Kenvue, Inc. (KVUE)
NYSE:KVUE
Top Page
Kenvue, Inc.
(NYSE:KVUE)
Select Model
Select Model
Rating:68Neutral
Price Target:
$20.50
â–²(17.95% Upside)
Action:ReiteratedDate:02/21/26
The score reflects solid underlying financial performance with some volatility and leverage risk, supported by constructive technical momentum. Offsetting factors include a not-cheap P/E (despite an attractive dividend yield) and corporate-event uncertainty from merger execution, litigation, and restructuring charges.
Positive Factors
Diversified consumer health portfolio
Kenvue’s broad portfolio across Self Care, Skin Health & Beauty and Essential Health supports recurring demand across channels and geographies. Diversification across categories and retail/e-commerce reduces single-category risk and underpins stable revenue streams over the medium term.
Negative Factors
Elevated leverage
Higher debt-to-equity and a reduced equity cushion limit balance-sheet flexibility. Elevated leverage increases interest and refinancing risk, constrains capacity for large bolt-on investments or unexpected costs, and makes the company more sensitive to cyclical earnings pressure during integration.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified consumer health portfolio
Kenvue’s broad portfolio across Self Care, Skin Health & Beauty and Essential Health supports recurring demand across channels and geographies. Diversification across categories and retail/e-commerce reduces single-category risk and underpins stable revenue streams over the medium term.
Read all positive factors
Kenvue, Inc. (KVUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.31B
Dividend Yield4.85%
Average Volume (3M)27.17M
Price to Earnings (P/E)22.4
Beta (1Y)0.04
Revenue Growth-2.94%
EPS Growth34.54%
CountryUS
Employees22,000
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.27
Shares Outstanding1,916,732,000
10 Day Avg. Volume21,011,460
30 Day Avg. Volume27,171,245
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue2.67
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda13.62
Forecast
1Y Price Target
$19.00Price Target Upside9.32% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)1.13
Revenue Forecast (FY)$15.54B
Kenvue, Inc. Business Overview & Revenue Model
Company Description
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, s...
How the Company Makes Money
Kenvue generates revenue primarily through the sale of its diverse portfolio of consumer health products. The company's revenue model is built around several key streams, including retail sales through pharmacies, supermarkets, and online platform...
Kenvue, Inc. Key Performance Indicators (KPIs)
Kenvue, Inc. Earnings Call Summary
Earnings Call Date:Jul 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.Positive Updates
Strong Market Share in Self Care
In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
Negative Updates
Disappointing Q2 Financial Performance
Organic sales declined 4.2% year-over-year, which was below expectations. Adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS fell to $0.29 from $0.32.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Market Share in Self Care
In the U.S., 83% of Kenvue's Self Care business held or gained market share, with ZYRTEC growing household penetration and Tylenol achieving its 12th consecutive quarter of share improvement.
Read all positive updates
Company Guidance
During Kenvue's Second Quarter 2025 Earnings Conference Call, the company revised its guidance for fiscal 2025, projecting organic sales to decline in the low single digits with a roughly neutral impact from currency fluctuations. The adjusted operating margin is expected to contract due to strategic price investments, fixed cost deleverage, and inflationary pressures, which productivity initiatives may not fully offset. Consequently, adjusted diluted EPS is anticipated to range between $1 to $1.05, considering a low single-digit drag from currency. The company highlighted a challenging second quarter, with organic sales declining by 4.2% and adjusted operating margin decreasing by 10 basis points to 22.7%, leading to an adjusted diluted EPS of $0.29. Despite these results, Kenvue remains committed to enhancing operational rigor, improving execution, and strategically reviewing alternatives to unlock shareholder value.Kenvue, Inc. Financial Statement Overview
Summary
Income Statement
73
Positive
Balance Sheet
62
Positive
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.12B | 15.46B | 15.44B | 14.95B | 15.05B |
| Gross Profit | 8.79B | 8.96B | 8.64B | 8.29B | 8.42B |
| EBITDA | 2.94B | 2.47B | 3.17B | 3.28B | 3.66B |
| Net Income | 1.47B | 1.03B | 1.66B | 2.06B | 2.08B |
Balance Sheet | |||||
| Total Assets | 27.08B | 25.60B | 27.85B | 27.32B | 27.93B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.07B | 1.38B | 1.23B | 740.00M |
| Total Debt | 8.52B | 8.72B | 8.43B | 9.05B | 129.00M |
| Total Liabilities | 16.31B | 15.93B | 16.64B | 7.35B | 7.53B |
| Stockholders Equity | 10.77B | 9.67B | 11.21B | 19.97B | 20.40B |
Cash Flow | |||||
| Free Cash Flow | 1.72B | 1.33B | 2.70B | 2.15B | 39.00M |
| Operating Cash Flow | 2.20B | 1.77B | 3.17B | 2.52B | 334.00M |
| Investing Cash Flow | -436.00M | -425.00M | -488.00M | -390.00M | -171.00M |
| Financing Cash Flow | -1.84B | -1.56B | -2.53B | -1.58B | 0.00 |
Kenvue, Inc. Technical Analysis
Negative
17.38
Price Trends
17.92
Negative
17.34
Positive
18.01
Negative
Market Momentum
-0.19
Positive
41.49
Neutral
32.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KVUE, the sentiment is Negative. The current price of 17.38 is below the 20-day moving average (MA) of 17.64, below the 50-day MA of 17.92, and below the 200-day MA of 18.01, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 41.49 is Neutral, neither overbought nor oversold. The STOCH value of 32.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KVUE.
Kenvue, Inc. Risk Analysis
Kenvue, Inc. disclosed 72 risk factors in its most recent earnings report. Kenvue, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kenvue, Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $334.87B | 20.05 | 31.23% | 2.92% | 1.23% | 17.97% | |
73 Outperform | $21.98B | 27.62 | 17.16% | 1.38% | 1.45% | 42.04% | |
69 Neutral | $121.32B | 12.84 | 26.01% | 3.74% | -0.30% | -14.60% | |
68 Neutral | $33.31B | 22.42 | 13.94% | 4.85% | -2.94% | 34.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $68.46B | -429.64 | 431.59% | 2.67% | -0.05% | 2.49% | |
61 Neutral | $32.39B | 16.63 | 155.28% | 5.03% | -10.04% | -23.41% |
* Consumer Defensive Sector Average
KVUE
Kenvue, Inc.
17.14
-5.51
-24.31%
CHD
Church & Dwight
92.85
-16.49
-15.08%
CL
Colgate-Palmolive
85.14
-8.55
-9.13%
KMB
Kimberly Clark
96.13
-42.91
-30.86%
PG
Procter & Gamble
143.12
-24.67
-14.70%
UL
Unilever
55.45
-9.39
-14.48%
Kenvue, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Kenvue Launches Workforce-Reducing Restructuring and Supply Chain Overhaul
Negative
Feb 17, 2026
On February 17, 2026, Kenvue’s board approved a restructuring initiative aimed at optimizing its operating model and transforming its supply chain, which will cut about 3.5% of its global workforce and generate roughly $250 million in pre-ta...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Kenvue Announces CFO Transition Amid Kimberly-Clark Transaction
Neutral
Feb 12, 2026
On February 10, Kenvue Inc. said Chief Financial Officer Amit Banati plans to step down from his role effective May 12, 2026, to become chief executive officer at another company. In light of its pending transaction with Kimberly-Clark Corporation...
Business Operations and StrategyM&A TransactionsShareholder Meetings
Kenvue shareholders overwhelmingly approve Kimberly-Clark merger plan
Positive
Jan 29, 2026
On January 29, 2026, Kenvue held a virtual special meeting at which approximately 78% of outstanding shares were represented, and about 99% of votes cast approved its previously announced merger agreement with Kimberly-Clark, clearing a key shareh...
Legal ProceedingsM&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Kenvue Supplements Proxy Disclosures Ahead of Merger Vote
Negative
Jan 16, 2026
On November 2, 2025, Kenvue Inc. agreed to be acquired by Kimberly-Clark Corporation through a two-step merger that would make Kenvue a wholly owned subsidiary of Kimberly-Clark, and by December 16, 2025, the SEC had declared effective a registrat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.